Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community

British Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2010, Pages 689-700

  Mangoni, Arduino A ^a   Woodman, Richard J ^a   Gaganis, Paraskevi ^a   Gilbert, Andrew L ^b   Knights, Kathleen M ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

COX 2 inhibitors; Elderly; Heart failure; Mortality; Myocardial infarction; Non steroidal anti inflammatory drugs

Indexed keywords

CELECOXIB; DICLOFENAC; DIFLUNISAL; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; TIAPROFENIC ACID;

AGED; ARTERY DISEASE; ARTICLE; AUSTRALIA; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VETERAN;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUSTRALIA; CASE-CONTROL STUDIES; CAUSE OF DEATH; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; VETERANS;

EID: 77952035460     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03627.x     Document Type: Article

References (87)

1. Prevalence and most common causes of disability among adults - United States, 2005. MMWR Morb Mortal Wkly Rep 2009 58 : 421 426.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 349 : 1498 1504. (Pubitemid 27216360)
3. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, Liu J, He J, Goldman L. The future impact of population growth and aging on coronary heart disease in China: projections from the coronary heart disease policy model-China. BMC Public Health 2008 8 : 394.
4. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979-2004. J Am Coll Cardiol 2008 52 : 428 434. (Pubitemid 352040814)
5. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005 142 : 157 164. (Pubitemid 40189107)
6. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005 3 : 17.
7. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005 165 : 978 984. (Pubitemid 40638117)
8. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 330 : 1366. (Pubitemid 40839565)
9. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclo-oxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005 142 : 481 489. (Pubitemid 40490913)
10. Jick H, Kaye JA, Russmann S, Jick SS. Nonsteroidal anti-inflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006 26 : 1379 1387. (Pubitemid 44521722)
11. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 2006 113 : 1950 1957. (Pubitemid 43754197)
12. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal anti-inflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006 54 : 1378 1389.
13. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclo-oxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006 113 : 2906 2913. (Pubitemid 44297231)
14. Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 2006 61 : 730 737. (Pubitemid 43794802)
15. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006 27 : 1657 1663. (Pubitemid 44025350)
16. Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007 93 : 189 194. (Pubitemid 46180292)
17. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008 52 : 1628 1636.
18. van Staa TP, Rietbrock S, Setakis E, Leufkens HG. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008 264 : 481 492.
19. Gibson CM, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis 2009 27 : 11 7.
20. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008 10 : 1102 1107.
21. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009 169 : 141 149.
22. Merlo J, Broms K, Lindblad U, Bjorck-Linne A, Liedholm H, Ostergren PO, Erhardt L, Rastam L, Melander A. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001 57 : 71 5. (Pubitemid 32391416)
23. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000 160 : 777 784. (Pubitemid 30165238)
24. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004 363 : 1751 1756. (Pubitemid 38698377)
25. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003 14 : 240 246. (Pubitemid 40417113)
26. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005 330 : 1370. (Pubitemid 40839570)
27. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998 158 : 1108 1112. (Pubitemid 28242315)
28. Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007 66 : 764 770. (Pubitemid 46846695)
29. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007 115 : 1634 1642. (Pubitemid 46648649)
30. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000 11 : 382 387. (Pubitemid 30428929)
31. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002 54 : 327 332. (Pubitemid 40471493)
32. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002 162 : 1099 1104. (Pubitemid 34522394)
33. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002 359 : 118 123. (Pubitemid 34112540)
34. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A. Effect of selective cyclo-oxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003 163 : 481 486. (Pubitemid 36241027)
35. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004 109 : 3000 3006. (Pubitemid 38808323)
36. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002 162 : 265 270. (Pubitemid 34127403)
37. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005 44 : 677 680. (Pubitemid 41487243)
38. McGettigan P, Han P, Jones L, Whitaker D, Henry D. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol 2008 65 : 927 934. (Pubitemid 351677430)
39. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008 17 : 822 833.
40. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug: a review. Clin Drug Invest 2002 22 : 799 818. (Pubitemid 36005678)
41. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999 96 : 7563 7568. (Pubitemid 29299702)
42. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 332 : 1302 1308. (Pubitemid 44365384)
43. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase 2. JAMA 2006 296 : 1633 1644. (Pubitemid 44511610)
44. King G, Zeng L. Estimating risk and rate levels, ratios and differences in case-control studies. Stat Med 2002 21 : 1409 1427. (Pubitemid 34495608)
45. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 1994 714 : 136 142. (Pubitemid 24197784)
46. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclo-oxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003 65 : 153 159. (Pubitemid 36015818)
47. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006 24 : 1457 1469.
48. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclo-oxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005 165 : 490 496. (Pubitemid 40344379)
49. Heidemann C, Hoffmann K, Klipstein-Grobusch K, Weikert C, Pischon T, Hense HW, Boeing H. Potentially modifiable classic risk factors and their impact on incident myocardial infarction: results from the EPIC-Potsdam study. Eur J Cardiovasc Prev Rehabil 2007 14 : 65 71. (Pubitemid 46271380)
50. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, Ruckley CV. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992 135 : 331 340.
51. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004 351 : 1709 1711.
52. Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the medical expenditure panel survey. Drug Saf 2009 32 : 335 343.
53. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007 14 : 55 61. (Pubitemid 44885613)
54. Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol 2008 173 : 1253 1264.
55. Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007 18 : 638 644.
56. Aneja A, Farkouh ME. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Ther Adv Cardiovasc Dis 2008 2 : 53 66. (Pubitemid 351583143)
57. White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep 2007 9 : 36 43. (Pubitemid 46806306)
58. Tegeder I, Geisslinger G. Cardiovascular risk with cyclo-oxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol 2006 373 : 1 17.
59. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001 89 : 650 660.
60. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006 92 : 1610 1615. (Pubitemid 44629166)
61. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004 90 : 464 470. (Pubitemid 38406929)
62. Rosen BD, Cushman M, Nasir K, Bluemke DA, Edvardsen T, Fernandes V, Lai S, Tracy RP, Lima JA. Relationship between C-reactive protein levels and regional left ventricular function in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2007 49 : 594 600. (Pubitemid 46177433)
63. Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 2008 10 : 63 9.
64. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 2006 152 : 514 520. (Pubitemid 44233424)
65. Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol 2004 4 : 171 176. (Pubitemid 38444053)
66. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal anti-inflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008 59 : 1097 1104.
67. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 365 : 475 481. (Pubitemid 40215729)
68. Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclo-oxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006 15 : 641 652. (Pubitemid 44404662)
69. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 286 : 954 959. (Pubitemid 33010342)
70. Zhang J, Ding EL, Song Y. Adverse effects of cyclo-oxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006 296 : 1619 1632. (Pubitemid 44511609)
71. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003 108 : 3006 3010. (Pubitemid 37553570)
72. Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, Aliot E, Zannad F, Serum BNP. hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 2007 9 : 724 729. (Pubitemid 47371644)
73. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 105 : 2595 2599. (Pubitemid 34596034)
74. Kim E, Joo S, Kim J, Ahn J, Kim J, Kimm K, Shin C. Association between C-reactive protein and QTc interval in middle-aged men and women. Eur J Epidemiol 2006 21 : 653 659. (Pubitemid 44730337)
75. Yue W, Schneider A, Ruckerl R, Koenig W, Marder V, Wang S, Wichmann HE, Peters A, Zareba W. Relationship between electrocardiographic and biochemical variables in coronary artery disease. Int J Cardiol 2007 119 : 185 191. (Pubitemid 46818520)
76. Fagbemi SO. The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias in anaesthetized rats. Eur J Pharmacol 1984 97 : 283 287.
77. Fagbemi O. The effects of the combined administration of beta-adrenoceptor antagonists and non-steroidal anti-inflammatory drugs on ligation-induced arrhythmias in rats. Br J Pharmacol 1985 85 : 361 365. (Pubitemid 16244034)
78. Tripathi RM, Kaushal R. Effect of some non-steroidal anti-inflammatory drugs on ouabain-induced arrhythmias in guinea-pigs. Br J Pharmacol 1988 93 : 747 750. (Pubitemid 18093379)
79. Cooper DR, Kelliher GJ, Kowey PR. Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. Am Heart J 1988 116 : 1194 1200.
80. Cheruku KK, Ghani A, Ahmad F, Pappas P, Silverman PR, Zelinger A, Silver MA. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol 2004 7 : 13 8.
81. Yang ZF, Wang HW, Zheng YQ, Zhang Y, Liu YM, Li CZ. Possible arrhythmiogenic mechanism produced by ibuprofen. Acta Pharmacol Sin 2008 29 : 421 429. (Pubitemid 351465504)
82. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007 99 : 881 889. (Pubitemid 47073510)
83. Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007 120 : 98 16. (Pubitemid 46026976)
84. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009 68 : 367 372.
85. Australia's Health 2008. Australian Institute of Health and Welfare, 2009 42 51.
86. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009 10 : 501 507.
87. Essebag V, Genest J Jr., Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003 146 : 581 590. (Pubitemid 37281701)